Is The Japanese Designated Marketing Authorization Holder Responsible For Pricing And Reimbursement Submissions?

In Japan, the Designated Marketing Authorization Holder (DMAH) is not directly responsible for pricing and reimbursement submissions. These tasks are typically handled by the Marketing Authorization Holder (MAH) or the pharmaceutical company itself, which collaborates with relevant authorities to navigate the complex pricing and reimbursement landscape in Japan.

Leave a Reply

You must be logged in to post a comment.